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Background: Inflammation and immune activation have repeatedly been suggested as pathogentic factors in
irritable bowel syndrome (IBS). The driving force for immune activation in IBS remains unknown. The aim of our
study was to find out if the obligate intracellular pathogen Chlamydia could be involved in the pathogenesis of
IBS.
Methods: We studied 65 patients (61 females) with IBS and 42 (29 females) healthy controls in which IBS had
been excluded. Full thickness biopsies from the jejunum and mucosa biopsies from the duodenum and the
jejunum were stained with a monoclonal antibody to Chlamydia lipopolysaccharide (LPS) and species-specific
monoclonal antibodies to C. trachomatis and C. pneumoniae. We used polyclonal antibodies to chromogranin A,
CD68, CD11c, and CD117 to identify enteroendocrine cells, macrophages, dendritic, and mast cells, respectively.
Results: Chlamydia LPS was present in 89% of patients with IBS, but in only 14% of healthy controls (p < 0.001)
and 79% of LPS-positive biopsies were also positive for C. trachomatis major outer membrane protein (MOMP).
Staining for C. pneumoniae was negative in both patients and controls. Chlamydia LPS was detected in
enteroendocrine cells of the mucosa in 90% of positive biopsies and in subepithelial macrophages in 69% of
biopsies. Biopsies taken at different time points in 19 patients revealed persistence of Chlamydia LPS up to 11
years. The odds ratio for the association of Chlamydia LPS with presence of IBS (43.1; 95% CI: 13.2-140.7) is much
higher than any previously described pathogenetic marker in IBS.
Conclusions: We found C. trachomatis antigens in enteroendocrine cells and macrophages in the small bowel
mucosa of patients with IBS. Further studies are required to clarify if the presence of such antigens has a role in
the pathogenesis of IBS.
Background
The irritable bowel syndrome (IBS) is a common dis-
order that may affect as many as 9%-15% of the popu-
lation in Western countries [1-3]. IBS is characterized
by abdominal pain and disturbed bowel function in
the absence of a detectable organic disease, which may
explain the symptoms [4]. The presence of disturbed
gut function in IBS may indicate an underlying pathol-
ogy in control systems or effectors of the gut. We
have previously reported lymphocytic infiltration and
neuron damage in myenteric ganglia when full-thick-
ness biopsies from the jejunum in 10 patients with
severe IBS were investigated [5], and there are many
reports that have highlighted signs of an activated
immune system as a putative pathogenetic mechanism
in IBS (for review see de Giorgio [6]). However, the
aetiology of observed immune activation remains
unsolved.
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after an acute gastroenteritis. The underlying mechan-
ism of post-infectious IBS has not been established but
ongoing inflammation appears to play a role, with an
increase in enteroendocrine cells, lymphocytes, mast
cells, and proinflammatory cytokines (for review, see
Spiller[7]). However, in a recent study of ours the actual
agent causing gastroenteritis was not a predictor of risk
for IBS [8]. Consequently, a host factor, such as a pre-
existing chronic infection with a different microbe than
the agent causing gastroenteritis, might explain the
development of IBS. We presumed that a candidate
agent should be compatible with an asymptomatic car-
rier-ship, have a preference for female gender, and have
the ability to become persistent and to live in bowel
epithelium. There are some observations to support the
idea that a persistent infection with Chlamydia tracho-
matis might constitute such a host factor. Trachoma-
related blindness is 2-4 times more likely to affect
females compared to males [9]. It is known that IBS
occurs in 35%-50% of females with chronic pelvic pain
syndrome, which is believed to often be caused by
chronic infection with C. trachomatis [10-12]. A pre-
vious attempt to link C. trachomatis to IBS using serum
IgG antibodies failed [13], but IgG antibody patterns
may be insufficient to rule out persistence of Chlamydia
due a dominating cellular immune response to infection
[14,15]. Since we had previously found inflammation in
mucosa and enteric ganglia of the jejunum in patients
with IBS we decided to reanalyze archived biopsy mate-
rial to find out if Chlamydia antigens are present in the
small bowel in this group of patients.
Methods
Patients
All patients fulfilled Rome-II criteria for IBS [4]. A total
of 65 patients (61 females and 4 males) with a median
age of 48 (range 22-67) years and a median duration of
IBS symptoms of 6.5 years (range 0.6-33.2 years) were
investigated. Diarrhoea predominant IBS was present in
21 patients (32%), 22 patients (34%) had constipation
predominant IBS and 22 patients (34%) had IBS with
alternating bowel habits. All patients had severe symp-
toms of IBS [5] and 26 patients also exhibited abnormal-
ities on small bowel manometry, thus qualifying for a
pathophysiological diagnosis of enteric dysmotility [16].
Full thickness jejunum biopsies had been taken in 60 of
our patients. Previous histopathological analysis had
revealed neuropathic changes in 58 patients [5,17,18].
Neuropathy was associated with low-grade inflammation
(LG = lymphocytic ganglionitis) in 46 patients and 20 of
these also exhibited increased numbers of intraepithelial
lymphocytes (LEG = lymphocytic epithelio-ganglionitis),
whereas 12 patients had degenerative neuropathy (DN)
without inflammation. Deficient staining for alpha-actin
without neuronal damage was observed in 2 patients.
Controls
The control group comprised 42 persons (29 females) in
whom IBS and all other functional bowel disorders had
been excluded by medical interview and a validated
questionnaire for the Rome-II symptom criteria. Ten
controls (7 females) were obese but otherwise healthy
(BMI mean = 42.8, SD = 4.3). The rest of the control
group (32 persons, 22 females) consisted of healthy
volunteers. The median age of the controls was 36
(range 19-60) years.
Full thickness jejunum biopsy
Previously obtained full-thickness biopsy specimens
were available in 60/65 patients. The biopsies had been
taken from the proximal jejunum using a laparoscopy-
assisted procedure described by Tornblom et al[5] Ten
obese controls underwent full thickness biopsy of the
jejunum at the time of gastric by-pass surgery.
Mucosa biopsy
Mucosa specimens from the proximal jejunum were
taken with a Watson capsule in 32 controls and 6
patients. The capsule was swallowed by the subject and
brought by peristalsis to a position distal to the ligament
of Treitz as determined by fluoroscopy. We analyzed
archived endoscopic mucosa biopsies from the duode-
num of 20 patients and in 15 of these full thickness
biopsies were also available. In 2 patients we analyzed
mucosa biopsies from both the jejunum and the
duodenum.
Immunofluorescence
Immunofluorescence was performed using a genus-spe-
cific mouse monoclonal antibody to Chlamydia lipopo-
lysaccharide (LPS)-FITC conjugated with Evans blue
(RDI-PROAC1FT, Fitzgerald Industries International,
Concord, MA, USA) and C. trachomatis major outer
membrane protein (MOMP) as primary antibody (Gene-
Tex, San Antonio, TX, USA) with a polyclonal rabbit
anti-mouse antibody-FITC conjugated (Dako, Glostrup,
Danmark) as the secondary antibody. We used cultured
HeLa-cells infected with C. trachomatis as positive con-
trol and uninfected cells as negative control. We used a
species-specific mouse monoclonal antibody for C.
pneumoniae as primary antibody (GeneTex, San Anto-
nio, TX, USA) with a polyclonal rabbit anti-mouse anti-
body-FITC conjugated (Dako, Glostrup, Denmark) as
the secondary antibody. The presence of Chlamydia
LPS was also evaluated using immunohistochemistry
with a polyclonal rabbit antibody to C. trachomatis LPS
(Fitzgerald Industries International, Concord, MA) and
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complex (Dako, Glostrup, Danmark).
Enteroendocrine cells were identified using rabbit
polyclonal antibodies to Chromogranin A (Abcam, Cam-
bridge, UK), and we used rabbit polyclonal antibodies to
CD117 (Dako, Glostrup, Denmark) for mast cells, rabbit
polyclonal antibodies to CD68 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) for macrophages and rabbit
monoclonal antibodies to CD11c (Abcam, Cambridge,
UK) for dendritic cells. Goat anti-rabbit antibodies con-
jugated with Alexa Fluor 568 or Alexia Fluor 350 (Invi-
trogen, Carlsbad, CA, USA) were used as secondary
antibody for all of the rabbit antibodies.
Stained sections were examined using a Universal
Laser Scanning Confocal Microscope System Leica TCS
and a Fluorescent Microscope System Leica DMRXA
(Leica Microsystems, Wetzlar, Germany). Two indepen-
dent investigators (AD and GM), who were unaware of
clinical data, made the final assessment of slides. The
slides were reviewed by a third investigator (BV). The
immunofluorescence stainings were considered positive
if more than one cell showed fluorescence. If only one
positive cell was found, the staining-procedure was
repeated. The case was regarded positive if the colour
signal was again present, otherwise the case was
recorded as negative. Double immunofluorescence stain-
ings were also performed for the identification of LPS-
positive cells (LPS with chromogranin, CD68, CD117, or
CD11c, respectively).
Western blotting
Snap-frozen biopsies from 4 patients that were positive
for Chlamydia LPS staining, were examined by Western
blotting. HeLa cells infected with C. trachomatis served
as positive control and we used non-infected HeLa cells
as negative control. Equivalent amounts of protein from
each specimen were loaded onto a sodium dodecyl sul-
phate-polyacrylamide gel. After electrophoresis, samples
were transferred to nitrocellulose membranes. We used
a mouse monoclonal antibody to C. trachomatis LPS
(AbD Serotec, Oxford, UK) as primary antibody and
goat anti-mouse antibody conjugated to horseradish per-
oxidase (BioRad, Herculaes, CA, USA) as secondary
antibody. For MOMP we used the same primary anti-
body as for immunofluorescence.
MicroLaser system
We used Laser Microdissection Pressure Catapulting
(LMPC) for laser based non-contact extraction of tissue
areas in paraffin embedded biopsies from 6 patients.
Regions of interest were manually delineated using
fluorescence microscopy and the LMPC software. Tissue
collection was achieved by laser cutting along the deli-
neation lines to separate tissue of interest from
surrounding regions, and secondly the laser catapulted
the tissue of interest up into the lid of an Eppendorf cap
containing sterile water. DNA was extracted using the
QIAamp DNA mini kit, according to the instructions of
the manufacturer, and analyzed by PCR.
Real-time PCR
In the present study, we used the real-time PCR assay
developed by Everett et al. [19], which amplifies 23S
ribosomal DNA, and detects all members of the family
Chlamydiaceae. An internal amplification control was
included to monitor possible inhibition of the PCR.
DNA from frozen biopsies, taken from 4 patients pre-
viously positive for Chlamydia LPS staining, was
extracted using a Qiagen minikit according to the tissue
protocol (Qiagen, Solna, Sweden). Extracted DNA was
quantified and quality controlled using a Nanodrop
spectrophotometer (Nanodrop Technologies, Wilming-
ton, DE, USA) before being subjected to PCR.
Transmission electron microscopy
Biopsies from the distal duodenum of 4 patients that
were positive for Chlamydia LPS staining were fixed
according to a procedure described before [20]. Semi-
thin sections were cut and stained with toluidin blue
and used for light microscopic analysis. Ultra-thin sec-
tions were contrasted with uranyl acetate followed by
lead citrate and examined in a Tecnai 10 transmission
electron microscope at 80 kV. Digital images were taken
by using a MegaView III digital camera (Soft Imaging
System, Münster, Germany).
Statistical analysis
We used logistic regression with age and gender as cov-
ariates for calculation of odds ratios and p-values for
comparisons of proportions. The size of the study group
was determined from the assumption that LPS positivity
would be no greater than 20% among controls. In order
to detect a risk factor with an odds ratio of at least 6 at
p < 0.01 with power >90% we needed to include at least
37 patients and 37 controls (two-sided test).
Ethical considerations
All parts of the study were approved by the Regional
Ethical Review Board in Stockholm. Informed consent
was obtained from all patients and controls at the time
of biopsy taking.
Results
Immunofluorescence (IF) staining showed that 53/60
patients were positive for Chlamydia LPS in full thick-
ness jejunum biopsies. Positive staining occurred in a
few cells both within the epithelium and in lamina pro-
pria (Figure 1). No Chlamydia LPS-positive cells were
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enteric nervous system. Since we had full thickness
biopsies from only 10 controls, we investigated if the
finding of LPS-positive cells could be reproduced in
biopsies from small bowel mucosa. We investigated
mucosal biopsies from 24 of our patients with IBS and
32 controls. Staining of slides from these biopsies
yielded similar rates of positive stainings: 21/24 (88%)
patients were positive for Chlamydia LPS again in a few
cells within the epithelium and in l. propria.I n1 9
patients biopsies had been taken with a time interval of
more than 1 year. Chlamydia LPS was present in biop-
sies with a median time difference of 5.2 (range 1-11)
years. Overall, 58/65 (89%) patients were classified as
Chlamydia LPS positive. Six women and one man with
IBS were negative in all biopsies.
In 90% of positive biopsies from patients Chlamydia
LPS was localised to mucosal cells at the level of the
crypts. Double staining with antibodies to chromogra-
nin-A showed that Chlamydia LPS was present in
Figure 1 Fluorescent microscope images of small bowel preparations from patients with IBS A. Chlamydia LPS in EEC-like cells with apical
nuclei and strong basal immunofluorescence (arrows). (Monoclonal FITC-conjugated antibody with Evans blue; original magnification × 63). B.
Chlamydia LPS in a few cells within the epithelium (thick arrows) and l. propria (thin arrows). (Monoclonal FITC-conjugated antibody with Evans
blue; original magnification × 63). C. Chlamydia trachomatis MOMP-positive immunofluorescence within 2 EEC-like cells (arrows) and 4 cells
within l. propria (arrowheads). (Mouse MOMP-antibody and FITC-conjugated rabbit anti-mouse antibody; original magnification × 63). Hoechst
(DAPI conjugated) for nuclear staining. D-F. Immunostainings for (D) Chlamydia LPS (FITC, green), (E) chromogranin A (Alexia 568, red), and (F)
merged showing co-localisation of chromogranin A and Chlamydia LPS in enteroendocrine cells and Chlamydia LPS in l. propria. G-I.
Immunostainings for (G) Chlamydia LPS (FITC, green,) (H) CD68 (Alexia 350. blue), and (I) merged showing co-localisation of CD68 and Chlamydia
LPS in macrophages (arrows). Three enteroendocrine cells are also positive for Chlamydia LPS (arrowheads).
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Chlamydia LPS was found in l. propria cells in 69% of
the biopsies from patients. Double staining with antibo-
dies to CD117, CD11c and CD68 revealed that in this
location Chlamydia LPS was present in macrophages.
Seventy-nine percent of Chlamydia LPS positive biop-
sies were also positive to C. trachomatis MOMP (Figure
1). Staining for C. pneumoniae was negative in all
patients.
Only 6/42 (14%) controls (5 women) were positive for
Chlamydia LPS (6 in l. propria macrophages and 2 in
enteroendocrine cells) and 2/6 LPS-positive controls
were positive to C. trachomatis MOMP. No biopsies
from controls were positive for C. pneumoniae.S l i d e s
from 10 patients who were positive for Chlamydia LPS
in immunofluorescence and 10 negative controls were
studied using immunohistochemistry with polyclonal
antibodies to Chlamydia LPS and streptavidin-biotin
complex. Chlamydia LPS was found in enteroendocrine
cells and/or macrophages in all cases whereas all con-
trols remained negative.
The prevalence of Chlamydia LPS was much higher in
patients with IBS (58/65) than it was among controls (6/
42). The odds ratio, corrected for differences in age and
gender distributions, for mucosal Chlamydia LPS being
indicative for presence of IBS was 43.1 (95% CI: 13.2-
140.7). Biopsies were analysed by two independent
investigators unaware of clinical data. The agreement
between the two investigators regarding individual biop-
sies was 94%, whereas their agreement regarding patient
classification was 100%.
We found no correlation between presence of Chla-
mydia antigens and the type of neuropathy in patients
with full thickness biopsies. Although the majority of
patients had neuropathy with inflammation, Chlamydia
antigens were common also among those who had neu-
ropathic changes without inflammation (LEG: 19/20 =
95%; LG 23/26 = 88%; DN 9/12 = 75%). We found no
difference between IBS subgroups with regard to positiv-
ity for Chlamydia antigens and 19/21 with D-IBS, 22/22
with C-IBS, and 17/22 with A-IBS were LPS positive.
New biopsies were taken from the duodenum mucosa
in 4 LPS-positive patients (Table 1). We confirmed the
presence of Chlamydia LPS antigen in patients with
Western blotting but the new biopsies were negative for
C. trachomatis MOMP both in immunofluorescense and
Western blot (Figure 2). Electron microscopy revealed
small oval structures resembling intermediate bodies of
Chlamydia with characteristic condensed nucleoids of
nucleic acid (Figure 3). Mitochondria were observed sur-
rounding the inclusions but did not appear to be in
close association with the inclusions. We were unable to
confirm the presence of Chlamydia DNA in the same
biopsies using 23S ribosomal DNA as target. Results
were negative for Chlamydia DNA also when we ana-
lyzed micro-dissected Chlamydia LPS positive cells.
Discussion
We report the novel finding of chlamydial antigens in
enteroendocrine cells and macrophages of the small
bowel mucosa in patients with severe IBS. LPS and
MOMP antigens were detected in mucosa and l. propria
of the small bowel in a large majority of patients with
IBS, but rarely so in healthy controls. The odds ratio for
mucosal Chlamydia LPS being indicative for presence of
IBS is much higher than any previously described
Table 1 Onset of disease and results from immunofluorescence staining for Chlamydia LPS and C. trachomatis MOMP,
Western blot, polymerase chain reaction (PCR), and electron microscopy (EM) in 4 patients selected for new biopsies





Year LPS MOMP LPS MOMP LPS MOMP 2007 2007
1 1994 1996 + + + - + - - +
2 1985 2000 + + + - + - - +
3 1968 2001 + + + - + - - +
4 1977 1997 + + + - + - - +
Figure 2 Western blot. Western blot analysis of small bowel
biopsies from 4 IBS patients against mouse immune sera to LPS
and MOMP, respectively. 1-4 = IBS patients, ++ = HeLa cells
infected with C. trachomatis (10 μl), + = HeLa cells infected with C.
trachomatis (5 μl), - = non-infected HeLa cells.
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several questions. The first is whether or not observed
immunofluorescence findings represent presence of bac-
terial antigens. The specificity of the LPS antibody is
important in this respect. There is a risk that antibodies
may give rise to unspecific binding but such binding
should not differ between patients and controls. We
therefore think that unspecific binding is an unlikely
explanation for our findings. It has previously been
shown that this monoclonal anti-LPS antibody does not
bind to environmental Chlamydiae [22,23]. The genus-
specific LPS epitope is not shared by other known
gram-negative bacteria and monoclonal antibodies do
not bind LPS of those organisms [24]. Thus, positive
staining of LPS can be considered as a marker of past or
present Chlamydia infection. We used different techni-
ques to visualize Chlamydia LPS. In addition to immu-
nofluorescence with a FITC-conjugated monoclonal
antibody, we used a polyclonal antibody to Chlamydia
LPS and the standard streptavidin-biotin technique for
light microscopy. The latter technique also showed pre-
sence of antigen in the same cell types. We used Wes-
tern blot on new biopsies from a limited number of
patients and confirmed that Chlamydia LPS was present
in the tissue samples from these patients. These findings
further support the hypothesis that observed antigens
have a bacterial origin.
The second question concerns the identity of the spe-
cies involved. We used a genus-specific antibody to
Chlamydia LPS and species-specific antibodies to C.
pneumoniae and C. trachomatis MOMP. Since we
found positive staining for C. trachomatis MOMP in
79% of Chlamydia LPS biopsies and none of them was
positive for C. pneumoniae we hypothesized that the
origin of these antigens is a past or present infection
with C. trachomatis.
The third question is if observed antigens represent an
ongoing infection or not. We investigated archived
biopsy material from the small bowel and this puts cer-
tain limits on our ability to ascertain the underlying
cause for observed findings as well as their specificity.
To confirm and strengthen our immunohistochemical
findings we used antibodies to different antigens and
also different methods of visualisation. In a limited
number of cases we had the opportunity to take new
biopsies for more advanced analyses using molecular
biology techniques, proteomics and electron microscopy.
Whereas electron microscopy showed presence of Chla-
mydia-like organisms in the cytoplasm of enteroendo-
crine cells, similar to those described in persistent C.
trachomatis infection [25], we were unable to detect
chlamydial DNA in a small number of patients using
standard extraction and amplification protocols. It is
possible that the standard methods we used for nucleic
Figure 3 Transmission electron microscopy. Electron micrograph of the cytoplasm of an enteroendocrine cell from a patient with IBS
showing a structure resembling an intermediate body of Chlamydia (arrow) with characteristic condensed nucleoids. Dark homogenous
structures are granules. M = Mitochondria, N = Nucleus, Bar = 0.5 μm.
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sistent infection [26]. Another explanation for the con-
tradictory results could be that chlamydial antigens were
remainders of a past, but no longer present infection
[27]. The latter seems unlikely in light of the long-term
presence of C. trachomatis antigens observed in several
of our patients. Long-term presence of antigens is more
likely to be attributable to replicating Chlamydiae resid-
ing in the diseased tissue [28]. At present, however, we
cannot determine if patients with severe IBS have an
ongoing intestinal infection with C. trachomatis or not.
Neither can we explain the presence of inflammation in
myenteric ganglia or neuropathy by the finding of Chla-
mydia antigens in enteroendocrine cells. A possible link
between the presence of Chlamydia antigens in enter-
oendocrine cells and myenteric inflammation could be
autoimmune mechanisms related to heat shock protein
60 [29], but at this time such a mechanism remains
purely speculative.
We found Chlamydia antigen also in macrophages. It
is known that Chlamydiae become spontaneously per-
sistent following the infection of monocytes and the
monocyte is the common host cell for Chlamydiae dur-
ing persistent infection [30-32]. Chlamydiae may partici-
pate in the maintenance of local immunological
response and inflammation via infected monocytes/
macrophages and also use them to spread infection to
other organs [33].
Some of our Chlamydia LPS positive patients did not
show the presence of MOMP antigen. Chlamydiae
down-regulate the major outer membrane protein
(MOMP) expression in the persistent state [34]. Attenu-
ated synthesis of MOMP, usually considered the
immuno-dominant surface epitope of the organism, in
combination with its almost exclusively intracellular
location during persistence may help to provide some
relative invisibility from immune surveillance [34].
The presence of C. trachomatis antigens in small
bowel mucosa has not been demonstrated in IBS
patients before. However, it is known that Chlamydiae
can persist in the intestinal mucosa of certain animals
for a long time without infection-induced inflammation
[35]. The specificity of C. trachomatis antigens for IBS
compared to other gastrointestinal diseases is unknown.
We did not have access to biopsies from the upper
small intestine of patients with for example Crohn’s dis-
ease or ulcerative colitis. At the same time, it is difficult
to rule out the co-existence of IBS with such diseases
and this might blur the results of such a comparison.
We therefore decided to compare our patients with
severe IBS to healthy controls in which IBS and other
motility disorders could be excluded.
The finding of C. trachomatis antigens in enteroendo-
crine cells makes it tempting to suggest a novel
pathogenetic mechanism in IBS. Enteroendocrine cells
play a pivotal role in the control of gut motility and
secretion and increased numbers of enteroendocrine
cells have been detected in patients that developed IBS
after an acute gastroenteritis [36]. It is unknown if infec-
tion alters the function of enteroendocrine cells in man
but animal experiments using different models of enteric
infection have shown pronounced changes in both num-
bers of enteroendocrine cells and their function [37,38].
Serotonin-producing enteroendocrine cells may present
an ideal location for Chlamydia due to their abundance
of tryptophan. Tryptophan is required for normal devel-
opment in Chlamydia species and tryptophan metabo-
lism has been implicated in Chlamydia persistence and
tissue tropism [39]. We hypothesize that Chlamydia
actively may enter EEC searching for tryptofan. Infection
may impair EEC serotonin and hormone secretion and
cause motility disturbances but further studies on enter-
oendocrine cell lines or cultured EEC are required for
elucidating such a mechanism.
Conclusions
We found chlamydial antigens in enteroendocrine cells
and macrophages of the small bowel mucosa in 89% of
patients with IBS but in only 14% of controls. Even
though we were unable to prove the presence of viable
Chlamydia, lack of positive PCR being the major obsta-
cle, the evidence for an intracellular organism or at least
a protein structure with an antigen in common with
Chlamydia in patients with IBS is strong. Our results
suggest that the presence of C. trachomatis antigens in
enteroendocrine cells may be involved in the pathogen-
esis in IBS.
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